Compare ResMed Inc. (RMD) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Shell PLC — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Shell PLC trades at $95.99 (market cap $271.34B). The key difference: Shell PLC is far larger — about 8.5× ResMed Inc.'s market cap, and Shell PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals.
| RMD | SHEL | |
|---|---|---|
Market Cap | $31.89B | $271.34B |
Sector | Health | Energy |
52-Week High | $283.28 | $95.60 |
52-Week Low | $182.82 | $70.31 |
Enterprise Value | $31.24B | $313.04B |
Dividend Yield | 1.19% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Shell (SHEL) trades at $95.32, up 2.55% on the day and near its record high, driven by strong crude oil prices and positive earnings momentum with recent quarterly beats. The stock shows a bullish technical outlook, supported by moving averages, while fundamentals reflect solid profitability with an 8.76% net margin and attractive valuation metrics like a P/E of 10.54. Recent developments include strategic acquisitions in deepwater projects and retail expansion, enhancing growth prospects.
The outlook for SHEL remains positive, with analyst consensus favoring a buy rating and a $101 price target, implying upside potential. Key opportunities include oil price tailwinds and operational efficiency, though risks involve revenue volatility from energy markets and geopolitical tensions, as highlighted by recent news. Investors should weigh robust cash flows against cyclical industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
